Clinical Trial: Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer

U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07695259) titled 'Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer' on Sept. 16, 2025.

Brief Summary: This is a single-center, interventional, prospective clinical study. A total of 45 patients aged >= 60 years with ECOG PS 0-1 who have histologically confirmed, treatment-naive, unilateral primary invasive HER-2-positive breast cancer will be enrolled according to predefined inclusion/exclusion criteria. Participants will receive olaparib 300 mg orally twice daily combined with investigator-selected HP regimen (trastuzumab 8 mg/kg C1 -> 6 mg/kg C2-6 and pertuzumab 840 mg C1 -> 420 mg C2-6, both q3w) for up to six neoadjuvan...